Zentalis Pharmaceuticals (ZNTL) Financials

Zentalis Pharmaceuticals (NASDAQ: ZNTL) remains a development-stage biotech with no product revenue, ongoing losses, and a balance sheet that is still funded by a sizable cash and investment position. Over the last several years, the company has consistently burned cash from operations, but it has also preserved a meaningful liquidity cushion through marketable securities and cash.

What stands out most in the latest quarter: in Q1 2026, Zentalis reported no revenue and a net loss of $35.4 million, which was broadly in line with the prior quarter. Operating cash burn remained heavy at $33.0 million, but the company still ended the period with $211.8 million in cash and short-term investments combined.

• Zentalis still has a substantial liquidity buffer, with $31.9 million in cash and $179.8 million in short-term investments at the end of Q1 2026.
• The company’s investment portfolio helped offset operating losses, producing $30.0 million of net cash from investing activities in Q1 2026.
• Cash and investments declined from $287.6 million at Q3 2025 to $211.8 million at Q1 2026, but the balance sheet remains solid for a clinical-stage biotech.
• Operating expenses were lower than earlier periods, with Q1 2026 total operating expenses of $37.9 million versus $45.6 million in Q1 2025 and $67.9 million in Q4 2023.
• Non-cash adjustments continue to support reported losses, which is common in biotech, and suggests much of the deficit is not pure cash expense.
• The company continues to carry a large accumulated deficit, reflected in retained earnings of negative $1.23 billion at Q1 2026.
• Zentalis has no revenue in the reported quarters from 2025 through Q1 2026, so performance depends entirely on pipeline execution and clinical milestones.
• Shares outstanding have stayed relatively stable, with basic weighted average shares around 70 million to 72 million in recent quarters.
• The company’s quarterly net loss has remained in a fairly tight range, roughly $27 million to $35 million in the last five reported quarters.
• Operating cash burn remains persistent, with Q1 2026 operating cash outflow of $33.0 million.
• The business is still unprofitable, reporting a Q1 2026 EPS loss of $0.50 and losses in every quarter shown.
• Cash and short-term investments have trended down significantly from $452.1 million in Q1 2024 to $211.8 million in Q1 2026.
• The company’s investing gains are partly driven by using its securities portfolio, which is helpful near term but not a long-term operating solution.

Longer-term trend: compared with Q1 2024, when Zentalis briefly showed revenue of $40.6 million and positive net income, the business has reverted to a pre-commercial profile with no revenue and recurring losses. Since then, revenue has disappeared, R&D and G&A spending have remained high, and cash has steadily been consumed.

Bottom line: Zentalis still has enough liquidity to continue operating in the near term, but the financial statements show a company that is burning cash and has not yet established a durable revenue base. For investors, the stock remains heavily dependent on pipeline progress, clinical readouts, and management’s ability to control spending while preserving capital.